Episode 61
Biotech Hangout
00:00
The Rise of Radiotherapeutics in Oncology
Timothy Stanley: Radiotherapeutics are really on the rise. He says it's going to be very hard for many of us to wrap our heads around earlier stage companies and programs. But clearly, it's an incredibly powerful modality; I'm surprised it's taken this long for the field to gain more momentum. Sloan: There is a very early data set for intra-viscular pad set for non-muscular invasive bladder cancers. That's a large opportunity that I don't think investors have generally been focused on for CGen or perhaps for Pfizer.
Transcript
Play full episode
